The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of the prognostic utility of miRNA and multiple genetic markers in stage IIA colon cancer.
Elizabeth Mambo
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen
Tiffany Sanford
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen
Kalyan Buddavarapu
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen
Alex Adai
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen
Paul A. Lebourgeois
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen
Karen Rasmussan
Employment or Leadership Position - Maine Medical Center
Lana Garmire
Employment or Leadership Position - Asuragen
Stock Ownership - Asuragen